Coassembled nanostructured bioscaffold reduces the expression of proinflammatory cytokines to induce apoptosis in epithelial cancer cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 5, 2016, Pages 1397-1407

  Li, Rui ^a,f   Pavuluri, Sivapriya ^a   Bruggeman, Kiara ^b   Long, Benjamin M ^a   Parnell, Andrew J ^c   Martel, Anne ^d   Parnell, Steven R ^e   Pfeffer, Frederick M ^a   Dennison, Andrew J C ^d,h   Nicholas, Kevin R ^a   Barrow, Colin J ^a   Nisbet, David R ^b   Williams, Richard J ^a,g  

^a DEAKIN UNIVERSITY   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d INSTITUT LAUE LANGEVIN   (France)

^e INDIANA UNIVERSITY   (United States)

^f INSTITUTE OF TROPICAL BIOSCIENCE AND BIOTECHNOLOGY   (China)

^g RMIT UNIVERSITY   (Australia)

^h TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bionanotechnology; Cancer; Hydrogels; Self assembly; Supramolecular materials; Tissue engineering

Indexed keywords

CELL DEATH; CELLS; DISEASES; GENE EXPRESSION; GENE EXPRESSION REGULATION; HYDROGELS; SELF ASSEMBLY; TISSUE ENGINEERING;

BIONANOTECHNOLOGY; CANCER; CANCER IMMUNOTHERAPY; EPITHELIAL CANCER CELLS; INNOVATIVE MATERIALS; PRO-INFLAMMATORY CYTOKINES; SELF-ASSEMBLED PEPTIDES; SUPRAMOLECULAR MATERIALS;

SCAFFOLDS (BIOLOGY);

FUCOIDIN; MOLECULAR SCAFFOLD; BIOMATERIAL; CYTOKINE; HYDROGEL; NANOFIBER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EPITHELIAL CANCER CELL LINE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; NANOPHARMACEUTICS; PROTEIN EXPRESSION; RIGIDITY; TONGUE CARCINOMA; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; NEOPLASM; TISSUE SCAFFOLD;

APOPTOSIS; BIOCOMPATIBLE MATERIALS; CYTOKINES; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; HYDROGELS; NANOFIBERS; NEOPLASMS, GLANDULAR AND EPITHELIAL; TISSUE SCAFFOLDS;

EID: 84962381534     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.009     Document Type: Article

References (62)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
2. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19(11):1423-1437.
3. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
4. Conde J., Bao C., Tan Y., Cui D., Edelman E.R., Azevedo H.S., Byrne H.J., Artzi N., Tian F. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater 2015, [n/a-n/a].
5. Cox T.R., Erler J.T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011, 4(2):165-178.
6. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
7. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5(12):1418-1423.
8. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10(5):501-507.
9. Yallapu M.M., Jaggi M., Chauhan S.C. Design and engineering of nanogels for cancer treatment. Drug Discov Today 2011, 16(9):457-463.
10. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24(24):4337-4351.
11. Wolinsky J.B., Colson Y.L., Grinstaff M.W. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012, 159(1):14-26.
12. Geiger B., Bershadsky A., Pankov R., Yamada K.M. Transmembrane crosstalk between the extracellular matrix and the cytoskeleton. Nat Rev Mol Cell Biol 2001, 2(11):793-805.
13. Whitesides G.M., Boncheva M. Beyond molecules: self-assembly of mesoscopic and macroscopic components. Proc Natl Acad Sci U S A 2002, 99(8):4769-4774.
14. Dias P.F., Siqueira J.M., Vendruscolo L.F., de Jesus Neiva T., Gagliardi A.R., Maraschin M., et al. Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum. Cancer Chemother Pharmacol 2005, 56(4):436-446.
15. Kim E.J., Park S.Y., Lee J.-Y., Park J.H. Fucoidan present in brown algae induces apoptosis of human colon cancer cells. BMC Gastroenterol 2010, 10(1):96.
16. Patel M.K., Mulloy B., Gallagher K.L., O'Brien L., Hughes A.D. The antimitogenic action of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells. Thromb Haemost 2002, 87(1):149-154.
17. Park H.Y., Kim G.Y., Moon S.K., Kim W.J., Yoo Y.H., Choi Y.H. Fucoidan inhibits the proliferation of human urinary bladder cancer t24 cells by blocking cell cycle progression and inducing apoptosis. Molecules 2014, 19(5):5981-5998.
18. Zhu C., Cao R., Zhang S.X., Man Y.N., Wu X.Z. Fucoidan inhibits the growth of hepatocellular carcinoma independent of angiogenesis. Evid Based Complement Alternat Med 2013, 2013:692549.
19. Murakami K., Aoki H., Nakamura S., Nakamura S.-i., Takikawa M., Hanzawa M., et al. Hydrogel blends of chitin/chitosan, fucoidan and alginate as healing-impaired wound dressings. Biomaterials 2010, 31(1):83-90.
20. Sezer A.D., Hatipoglu F., Cevher E., Oğurtan Z., Bas A.L., Akbuğa J. Chitosan film containing fucoidan as a wound dressing for dermal burn healing: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech 2007, 8(2):1530-9932.
21. Worthington P., Pochan D.J., Langhans S.A. Peptide hydrogels-versatile matrices for 3D cell culture in cancer medicine. Front Oncol 2015, 5.
22. Rodriguez A.L., Wang T.Y., Bruggeman K.F., Horgan C.C., Li R., Williams R.J., et al. In vivo assessment of grafted cortical neural progenitor cells and host response to functionalized self-assembling peptide hydrogels and the implications for tissue repair. J Mater Chem B 2014, 2(44):7771-7778.
23. Modepalli V.N., Rodriguez A.L., Li R., Pavuluri S., Nicholas K.R., Barrow C.J., et al. In vitro response to functionalized self-assembled peptide scaffolds for three-dimensional cell culture. Pept Sci 2014, 102(2):197-205.
24. Zhou M., Smith A.M., Das A.K., Hodson N.W., Collins R.F., Ulijn R.V., Gough J.E. Self-assembled peptide-based hydrogels as scaffolds for anchorage-dependent cells. Biomaterials 2009, 30(13):2523-2530.
25. Nisbet D., Williams R. Self-assembled peptides: characterisation and in vivo response. Biointerphases 2012, 7(1):1-14.
26. Boekhoven J., Stupp S.I. 25th anniversary article: supramolecular materials for regenerative medicine. Adv Mater 2014.
27. Rodriguez A., Wang T.-Y., Bruggeman K., Li R., Williams R., Parish C., et al. Tailoring minimalist self-assembling peptides for localized viral vector gene delivery. Nano Res 2015, 1-11.
28. Williams R.J., Smith A.M., Collins R., Hodson N., Das A.K., Ulijn R.V. Enzyme-assisted self-assembly under thermodynamic control. Nat Nanotechnol 2009, 4(1):19-24.
29. Rodriguez A.L., Parish C.L., Nisbet D.R., Williams R.J. Tuning the amino acid sequence of minimalist peptides to present biological signals via charge neutralised self assembly. Soft Matter 2013, 9:3915-3919.
30. Li R., Horgan C.C., Long B., Rodriguez A.L., Mather L., Barrow C.J., et al. Tuning the mechanical and morphological properties of self-assembled peptide hydrogels via control over the gelation mechanism through regulation of ionic strength and the rate of pH change. RSC Adv 2015, 5(1):301-307.
31. Williams R.J., Hall T.E., Glattauer V., White J., Pasic P.J., Sorensen A.B., et al. The in vivo performance of an enzyme-assisted self-assembled peptide/protein hydrogel. Biomaterials 2011, 32(22):5304-5310.
32. Javid N., Roy S., Zelzer M., Yang Z., Sefcik J., Ulijn R.V. Cooperative self-assembly of peptide gelators and proteins. Biomacromolecules 2013, 14(12):4368-4376.
33. Zhao F., Ma M.L., Xu B. Molecular hydrogels of therapeutic agents. Chem Soc Rev 2009, 38(4):883-891.
34. Yang Z.M., Xu K.M., Wang L., Gu H.W., Wei H., Zhang M.J., Xu B. Self-assembly of small molecules affords multifunctional supramolecular hydrogels for topically treating simulated uranium wounds. Chem Commun 2005, 35:4414-4416.
35. Bhuniya S., Seo Y.J., Kim B.H. Ibuprofen-based hydrogelators: an approach toward anti-inflammatory drug delivery. Tetrahedron Lett 2006, 47(40):7153-7156.
36. Dewhurst C.D. D33-a third small-angle neutron scattering instrument at the Institut Laue Langevin. Meas Sci Technol 2008, 19(3):8.
37. Kline S.R. Reduction and analysis of SANS and USANS data using IGOR Pro. J Appl Crystallogr 2006, 39:895-900.
38. Rheinwald J.G., Beckett M.A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 1981, 41(5):1657-1663.
39. Smith A.M., Williams R.J., Tang C., Coppo P., Collins R.F., Turner M.L., et al. Fmoc-diphenylalanine self assembles to a hydrogel via a novel architecture based on pi-pi interlocked beta-sheets. Adv Mater 2008, 20(1):37-41.
40. Hirst A.R., Roy S., Arora M., Das A.K., Hodson N., Murray P., et al. Biocatalytic induction of supramolecular order. Nat Chem 2010, 2(12):1089-1094.
41. Raeburn J., Adams D.J. Multicomponent low molecular weight gelators. Chem Commun 2015, 51(25):5170-5180.
42. Adams D.J., Butler MF, Frith WJ, Kirkland M., Mullen L., Sanderson P. Tailoring gel strength by amino acid sequence in fmoc dipeptide hydrogels. Soft Matter 2009, 5:1856-1862.
43. Cheng G., Castelletto V., Moulton C.M., Newby G.E., Hamley I.W. Hydrogelation and self-assembly of fmoc-tripeptides: unexpected influence of sequence on self-assembled fibril structure, and hydrogel modulus and anisotropy. Langmuir 2010, 26(7):4990-4998.
44. Lirdprapamongkol K., Warisnoicharoen W., Soisuwan S., Svasti J. Eco-friendly synthesis of fucoidan-stabilized gold nanoparticles. Am J Appl Sci 2010, 7(8):1038.
45. Williams R.J., Gardiner J., Sorensen A.B., Marchesan S., Mulder R.J., McLean K.M., et al. Monitoring the early stage self-assembly of enzyme-assisted peptide hydrogels. Aust J Chem 2013, 66(5):572-578.
46. Sayes C.M., Wahi R., Kurian P.A., Liu Y., West J.L., Ausman K.D., et al. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol Sci 2006, 92(1):174-185.
47. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6(5):392-401.
48. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59(19):5002-5011.
49. Hamill K.J., Hopkinson S.B., Hoover P., Todorović V., Green K.J., Jones J.C. Fibronectin expression determines skin cell motile behavior. J Investig Dermatol 2012, 132(2):448-457.
50. Kuang Y., Yuan D., Zhang Y., Kao A., Du X., Xu B. Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules. RSC Adv 2013, 3(21):7704-7707.
51. Massia S.P., Hubbell J.A. An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation. J Cell Biol 1991, 114(5):1089-1100.
52. Maheshwari G., Brown G., Lauffenburger D.A., Wells A., Griffith L.G. Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci 2000, 113(10):1677-1686.
53. Morris K.L., Chen L., Raeburn J., Sellick O.R., Cotanda P., Paul A., et al. Chemically programmed self-sorting of gelator networks. Nat Commun 2013, 4:1480.
54. Nakano Y., Kobayashi W., Sugai S., Kimura H., Yagihashi S. Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma. Jpn J Cancer Res 1999, 90(8):858-866.
55. Reuter S., Charlet J., Juncker T., Teiten M.H., Dicato M., Diederich M. Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann N Y Acad Sci 2009, 1171:436-447.
56. Rao S.K., Pavicevic Z., Du Z., Kim J.G., Fan M., Jiao Y., et al. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 2010, 285(42):32512-32521.
57. Waseem A., Ali M., Odell E.W., Fortune F., Teh M.T. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010, 46(7):536-542.
58. Tao J., Zhi X., Tian Y., Li Z., Zhu Y., Wang W., et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol 2014, 35(5):4389-4399.
59. Ko S.C., Huang C.R., Shieh J.M., Yang J.H., Chang W.C., Chen B.K. Epidermal growth factor protects squamous cell carcinoma against cisplatin-induced cytotoxicity through increased interleukin-1beta expression. PLoS One 2013, 8(2):e55795.
60. Lin A., Karin M. NF-κB in cancer: a marked target. Seminars in cancer biology 2003, 107-114. Elsevier.
61. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Investig 2001, 107(2):135.
62. Yu C., Young S., Russo V., Amsden B.G., Flynn L.E. Techniques for the isolation of high-quality RNA from cells encapsulated in chitosan hydrogels. Tissue Eng Part C Methods 2013, 19(11):829-838.